Stock Analysis on Net
Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Thermo Fisher Scientific Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021 Dec 31, 2020 Sep 26, 2020 Jun 27, 2020 Mar 28, 2020 Dec 31, 2019 Sep 28, 2019 Jun 29, 2019 Mar 30, 2019
Short-term obligations and current maturities of long-term obligations 3.66 4.94 5.12 6.47 5.74 1.12 1.12 2.01 2.67 0.03 0.01 0.01 3.81 0.00 1.10 1.26 1.16 1.17 4.10 2.40
Accounts payable 2.91 2.58 2.57 2.96 3.48 2.73 2.85 2.88 3.01 3.13 3.10 3.25 3.15 2.66 2.25 2.72 3.29 2.92 2.40 2.63
Accrued payroll and employee benefits 1.62 1.50 1.39 1.38 2.16 2.06 1.90 1.76 2.55 2.47 2.20 1.99 2.77 2.40 1.92 1.29 1.73 1.56 1.40 1.27
Contract liabilities 2.72 2.62 2.75 2.81 2.68 2.84 3.01 3.10 2.79 1.96 2.17 2.12 1.84 1.63 1.58 1.60 1.57 1.66 1.83 1.74
Other accrued expenses 3.29 2.93 3.16 3.16 3.45 3.54 3.26 3.27 3.10 2.96 2.75 3.24 3.35 3.03 2.91 2.50 2.87 2.99 3.23 2.57
Current liabilities 14.19% 14.59% 15.00% 16.78% 17.51% 12.28% 12.14% 13.01% 14.12% 10.53% 10.23% 10.61% 14.92% 9.72% 9.76% 9.37% 10.61% 10.30% 12.95% 10.61%
Deferred income taxes 1.95 2.70 3.02 3.14 2.93 3.47 3.67 3.77 4.03 1.99 2.41 2.86 2.60 2.39 2.84 3.64 3.75 3.53 3.34 3.86
Other long-term liabilities 4.70 4.46 4.30 4.47 4.36 4.86 5.01 5.03 4.77 5.41 5.19 5.08 4.84 5.29 5.39 5.56 5.55 5.53 5.40 5.48
Long-term obligations, excluding current maturities 31.71 31.41 31.02 30.78 29.76 31.09 32.29 33.84 33.99 29.47 27.73 28.27 27.67 32.92 33.51 32.77 29.25 28.90 28.74 30.24
Long-term liabilities 38.36% 38.57% 38.34% 38.39% 37.05% 39.42% 40.97% 42.64% 42.80% 36.87% 35.33% 36.22% 35.11% 40.60% 41.73% 41.97% 38.56% 37.95% 37.49% 39.58%
Total liabilities 52.55% 53.16% 53.33% 55.17% 54.56% 51.70% 53.11% 55.65% 56.92% 47.40% 45.56% 46.83% 50.03% 50.32% 51.50% 51.34% 49.17% 48.25% 50.44% 50.19%
Redeemable noncontrolling interest 0.12 0.12 0.12 0.13 0.12 0.13 0.13 0.12 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Preferred stock, $100 par value; none issued 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, $1 par value 0.45 0.46 0.47 0.47 0.45 0.49 0.49 0.47 0.46 0.60 0.65 0.66 0.63 0.68 0.71 0.74 0.74 0.77 0.75 0.78
Capital in excess of par value 17.51 17.69 18.10 17.84 17.23 18.33 18.18 17.57 17.00 21.68 23.38 23.79 22.56 24.14 24.90 25.88 25.80 26.38 25.68 26.57
Retained earnings 47.98 47.26 47.06 45.49 43.14 44.68 43.14 40.46 37.25 46.03 47.38 46.03 40.72 40.13 38.74 38.83 37.84 37.31 35.33 34.96
Treasury stock at cost -15.33 -15.58 -16.03 -15.93 -12.37 -12.16 -12.10 -11.82 -9.38 -12.11 -13.08 -13.43 -9.87 -10.64 -10.99 -11.53 -8.97 -7.91 -7.66 -7.99
Accumulated other comprehensive loss -3.27 -3.12 -3.11 -3.23 -3.19 -3.23 -3.01 -2.53 -2.45 -3.61 -3.88 -3.89 -4.07 -4.64 -4.85 -5.26 -4.59 -4.80 -4.54 -4.51
Total Thermo Fisher Scientific Inc. shareholders’ equity 47.34% 46.70% 46.49% 44.64% 45.27% 48.10% 46.69% 44.16% 42.88% 52.60% 54.44% 53.17% 49.97% 49.68% 48.50% 48.66% 50.83% 51.75% 49.56% 49.81%
Noncontrolling interests -0.01 0.02 0.05 0.06 0.06 0.07 0.07 0.07 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total equity 47.33% 46.72% 46.55% 44.70% 45.32% 48.17% 46.76% 44.23% 42.95% 52.60% 54.44% 53.17% 49.97% 49.68% 48.50% 48.66% 50.83% 51.75% 49.56% 49.81%
Total liabilities, redeemable noncontrolling interest and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Thermo Fisher Scientific Inc. current liabilities as a percentage of total liabilities, redeemable noncontrolling interest and equity decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Thermo Fisher Scientific Inc. long-term liabilities as a percentage of total liabilities, redeemable noncontrolling interest and equity increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Thermo Fisher Scientific Inc. total liabilities as a percentage of total liabilities, redeemable noncontrolling interest and equity decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total Thermo Fisher Scientific Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Thermo Fisher Scientific Inc. total Thermo Fisher Scientific Inc. shareholders’ equity as a percentage of total liabilities, redeemable noncontrolling interest and equity increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.